We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site
Cell line development (CLD) on the Beacon® optofluidic system enables selection of the best production cell lines with >99% monoclonality assurance in just days. The new Opto™ CLD 2.0 workflow extends these capabilities to allow (1) enrichment of rare cell populations, (2) on-chip titer measurements for traditional and non-traditional antibody molecules, and (3) efficient recovery of top clones for scale-up.
Learn about improved and expedited cell line development on the Beacon platform from Biogen’s Rachel Ferguson.
Watch a 1-hour webinar from the 2018 BioProcess International Digital Week titled, “Implementing the Beacon Platform for the Next Generation of Cell Line Development,” featuring scientists from Berkeley Lights and Catalent Biologics.
Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.